- Celcuity got its cancer drug approved. Then its stock dippedThe FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the drug could take until the end of the quarter to launch. ...Endpoints · 6d ago↗ source
- GSK plans large study to see if shingles vaccine can prevent dementiaLONDON — Over the past several years, data scientists searching through national health records have noticed something surprising about people who had been vaccinated for shingles: They were less l…Endpoints · 7d ago↗ source
- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury,…